{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-016075","form_type":"8-K","ticker":"RNGE","cik":"0001438943","company_name":"RANGE IMPACT, INC.","filed_at":"2024-04-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.433325+00:00","generated_at":"2026-06-03T06:22:56.718312+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Range Impact promotes Patricia Missal to CFO, plans divestiture of Graphium subsidiary","bullets":["Patricia Missal promoted from Controller to CFO, replacing Richard McKilligan, effective April 25, 2024.","Missal receives annual base salary of $225,000 and options to purchase 250,000 shares with vesting terms.","Dr. Brandon Zipp and Richard McKilligan transition to Graphium Biosciences roles for proposed divestiture.","Range Impact engaged First Liberties Financial in Dec. 2023 to help raise capital for Graphium divestiture."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-016075","json":"https://secwatch.observer/filing/0001493152-24-016075.json","markdown":"https://secwatch.observer/filing/0001493152-24-016075.md","text":"https://secwatch.observer/filing/0001493152-24-016075.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1438943/000149315224016075/0001493152-24-016075-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1438943/000149315224016075/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T06:22:56.718312+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"49b9983a99","claim":"Richard McKilligan changed role as Chief Financial Officer of Graphium Biosciences, Inc. at RANGE IMPACT, INC..","evidence_excerpt":"Mr. McKilligan will remain as Chief Financial Officer of Graphium Biosciences, Inc., a wholly-owned subsidiary of the Company (“Graphium”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1438943/000149315224016075/0001493152-24-016075-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"will remain as"},{"label":"Role","value":"Chief Financial Officer of Graphium Biosciences, Inc."}],"fact_type":"executive_change"},{"claim_id":"84fc6f518f","claim":"Patricia Missal was elected as Chief Financial Officer at RANGE IMPACT, INC..","evidence_excerpt":"On April 25, 2024, the Board of Directors of Range Impact, Inc. (the “Company”) elected Patricia Missal as Chief Financial Officer, replacing Richard McKilligan who had previously served as the Company’s Chief Financial Officer, Counsel and Secretary.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1438943/000149315224016075/0001493152-24-016075-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"elected"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"f20669538d","claim":"Dr. Brandon Zipp changed role as Chief Science Officer of Graphium at RANGE IMPACT, INC..","evidence_excerpt":"Dr. Brandon Zipp, who had served as the Company’s Chief Science Officer, will, effective April 25, 2024, serve exclusively as the Chief Science Officer of Graphium.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1438943/000149315224016075/0001493152-24-016075-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"serve exclusively as"},{"label":"Role","value":"Chief Science Officer of Graphium"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}